TIL Instil Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789769 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY71.9%
TTM EPS YoY73.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-19.2%
ROA-10.4%
ROIC (approx.)-21.8%
Asset turnover—
Leverage & solvency
Liabilities / assets47.6%
Debt / equity0.00x
Current ratio10.42x
Interest coverage-4.69x
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $233,000 | $270,000 | $669,000 | $3.50M | $9.13M | $6.74M | $5.37M | $1.10M |
| SG&A expense | $5.83M | $5.71M | $5.97M | $6.06M | $6.34M | $6.16M | $9.11M | $10.37M |
| Operating income | -$5.99M | -$6.16M | -$7.63M | -$9.56M | -$15.47M | -$23.44M | -$30.56M | -$11.82M |
| Interest expense | $1.55M | $1.58M | $1.55M | $1.57M | $1.58M | $1.58M | $1.10M | $3.00M |
| Net income | -$4.23M | -$4.42M | -$4.37M | -$8.19M | -$13.59M | -$21.39M | -$28.51M | -$11.89M |
| EBITDA | -$5.29M | -$5.96M | -$7.62M | -$9.54M | -$15.46M | -$23.44M | -$30.06M | -$11.08M |
| EPS (basic) | -0.62 | -0.65 | -0.64 | — | -2.01 | -3.24 | -4.32 | — |
| EPS (diluted) | -0.62 | -0.65 | -0.64 | — | -2.01 | -3.24 | -4.32 | — |
| Weighted avg. shares (diluted) | 6.78M | 6.78M | 6.78M | — | 6.76M | 6.60M | 6.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.54M | $5.54M | $5.02M | $6.64M | $6.08M | $7.84M | $16.33M | $10.63M |
| Short-term investments | $59.53M | — | — | $69.49M | — | — | — | — |
| Current assets | $65.51M | $73.11M | $189.67M | $192.42M | $196.26M | $207.39M | $219.26M | $124.47M |
| PP&E, net | $111.10M | $111.78M | $112,000 | $126,000 | $138,000 | $150,000 | $162,000 | $129.41M |
| Total assets | $195.65M | $199.22M | $201.80M | $204.51M | $211.77M | $230.99M | $237.45M | $263.57M |
| Current liabilities | $6.29M | $6.29M | $7.46M | $7.03M | $5.70M | $13.85M | $7.23M | $7.90M |
| Total liabilities | $93.08M | $93.32M | $92.46M | $91.84M | $91.35M | $99.32M | $92.54M | $94.13M |
| Shareholders' equity | $102.56M | $105.90M | $109.34M | $112.67M | $118.94M | $130.19M | $143.43M | $168.27M |
| Shares outstanding | 6.78M | 6.78M | 6.78M | 6.78M | 6.78M | 6.75M | 6.56M | 6.53M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.40M | -$4.64M | -$1.34M | -$7.08M | -$10.56M | -$14.79M | -$4.20M | -$10.56M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$10.56M |
| Investing cash flow | -$155,000 | $5.29M | -$317,000 | $7.82M | $8.45M | -$400,000 | $9.61M | $13.00M |
| Financing cash flow | -$300,000 | $0 | $0 | $0 | $378,000 | $6.68M | $232,000 | $1.60M |
| Depreciation & amortization | $700,000 | $200,000 | $12,000 | $12,000 | $10,000 | $0 | $498,000 | $741,000 |
| Stock-based compensation | $984,000 | $1.04M | $985,000 | $1.61M | $1.77M | $1.82M | $3.50M | $4.50M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.